Corrixr Therapeutics
Destroying some of the deadliest squamous cell cancers at their source.
7 employees · est. 2022 · Newark, United States
Kronos Bio
We’re focused on creating a world where no life is cut short by cancer or other serious diseases.
70 employees · est. 2017 · San Mateo, United States
Kronos Bio is the older company (2022 vs 2017); Kronos Bio is the larger of the two.
1 signal in the last 90 days
Side-by-Side Comparison
| Metric | Corrixr Therapeutics | Kronos Bio |
|---|---|---|
| Founded | ||
| Founded | 2022 | 2017 older |
| Headquarters | ||
| Headquarters | Newark, United States | San Mateo, United States |
| Employees | ||
| Employees | 7 | 70 larger |
| Industry | ||
| Industry | Biotechnology, Health Care, Health and Wellness | Biotechnology, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Seed | Private Equity |
| Total Funding | ||
| Total Funding | $6.53M | $278.00M |
| Funding Rounds | ||
| Funding Rounds | 2 | 3 |
| Services | ||
| Services | Development of targeted genetic therapies, Disabling NRF2 in squamous cell cancers, Localized genetic delivery to tumors | Not tracked yet |
| Target Customers | ||
| Target Customers | Patients with lung squamous cell carcinoma, Patients with head & neck squamous cell carcinoma, Patients with esophageal squamous cell carcinoma, Oncologists seeking innovative treatments, Healthcare providers specializing in oncology | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Oncology, Biotherapeutics, Gene Editing, CRISPR/Cas, Pre-clinical Stage, Gene Therapy, Solid Tumors, Clinical Frontier, Therapeutic Platform, Drug-resistant, Innovation, Precision Medicine, Clinical Trials, Oncology Research | Biopharmaceutical Company, Clinical-stage, Therapeutics, CDK9 Inhibitor, Transcription Factor, Oncology, Cancer Treatment, Myc-dependent Tumors, Transcriptional Addiction, Discovery Collaboration, Genentech Partnership, P300 KAT Domain, Multiple Myeloma, Transcriptional Targets, Precision Medicine |
| Website | ||
| Website | corrixr.com | kronosbio.com |
About Corrixr Therapeutics
CorriXR Therapeutics, founded in 2022, is an emerging force in the biotechnology and health care sectors. Based in the United States, the company is carving out a niche in the development of oncology-focused biotherapeutics through its revolutionary in vivo gene editing platform. The company is uti...
About Kronos Bio
Kronos Bio is a clinical-stage biopharmaceutical company with a mission to combat cancer and serious diseases by targeting dysregulated transcription. The company's current pipeline includes KB-0742, a CDK9 inhibitor under evaluation for MYC-dependent tumors and KB-9558, targeting the KAT domain of...
We will tell you when either one moves
BounceWatch watches Corrixr Therapeutics and Kronos Bio for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Corrixr Therapeutics and Kronos Bio — by email.
Frequently Asked Questions
Compare Corrixr Therapeutics with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Corrixr Therapeutics on 12 Sep 2024, and Kronos Bio on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.